Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

Chapel Hill, North Carolina


Purpose:

To evaluate the rate of complete pathological response after 3 cycles of gemcitabine containing chemotherapy.


Criteria:

Inclusion Criteria: - Histologically or cytologically confirmed non small cell lung cancer - No prior chemotherapy or radiation for non small cell lung cancer - No prior malignancy Exclusion Criteria: - Pregnancy or breastfeeding - Serious concomitant disorders


NCT ID:

NCT00191256


Primary Contact:

Study Director
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon-Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
Eli Lilly and Company


Backup Contact:

N/A


Location Contact:

Chapel Hill, North Carolina
United States



There is no listed contact information for this specific location.

Site Status: N/A


Data Source: ClinicalTrials.gov

Date Processed: November 18, 2019

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.